A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients

Ingrida Janulevicienë, Alon Harris, L. Kagemann, Brent Siesky, L. McCranor

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose: To evaluate the effects of dorzolamide/timolol fixed combination (D/T) compared to latanoprost on intraocular pressure (IOP) and pulsatile ocular blood flow (POBF) in primary open-angle glaucoma (POAG) patients. Methods: Thirty patients with POAG were randomized in an open-label, cross-over study. Intraocular pressure reduction was achieved by 4 weeks medical therapy with D/T twice daily or latanoprost 0.005% dosed once in the evening. During a 4-week run-in and a 4-week wash-out period between study arms, patients ceased use of all other glaucoma medications and used timolol maleate 0.5% twice daily. Primary efficacy variables were IOP and POBF. Results: There was no difference in baseline IOP and POBF parameters between the two study arms. Both D/T and latanoprost statistically significantly reduced IOP by 4.6 mmHg (p<0.0001) and 3.75 mmHg (p< 0.0001) and increased POBF by 2.048 μl/second (p = 0.0030) and 2.147μl/second (p = 0.0009), respectively. Repeated measures ANOVA detected significant changes in POBF with treatment (p = 0.0361). Dorzolamide/timolol fixed combination statistically significantly increased pulse volume by 0.767μl (p = 0.0087), while latanoprost therapy had no significant effect (p = 0.2407). Conclusions: Both drugs had similar effects in terms of IOP reduction. Dorzolamide/timolol significantly increased pulse volume while latanoprost had no effect. Further studies are necessary to establish whether the enhancement of choroidal blood flow can prevent glaucoma progression.

Original languageEnglish
Pages (from-to)730-737
Number of pages8
JournalActa Ophthalmologica Scandinavica
Volume82
Issue number6
DOIs
StatePublished - Dec 2004

Fingerprint

latanoprost
Intraocular Pressure
Timolol
dorzolamide
Glaucoma
Cross-Over Studies
dorzolamide-timolol combination
Primary Open Angle Glaucoma
Analysis of Variance
Therapeutics

Keywords

  • Glaucoma
  • Intraocular pressure
  • Pulsatile ocular blood flow

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{aef58324f3ec4d018757990ef57058eb,
title = "A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients",
abstract = "Purpose: To evaluate the effects of dorzolamide/timolol fixed combination (D/T) compared to latanoprost on intraocular pressure (IOP) and pulsatile ocular blood flow (POBF) in primary open-angle glaucoma (POAG) patients. Methods: Thirty patients with POAG were randomized in an open-label, cross-over study. Intraocular pressure reduction was achieved by 4 weeks medical therapy with D/T twice daily or latanoprost 0.005{\%} dosed once in the evening. During a 4-week run-in and a 4-week wash-out period between study arms, patients ceased use of all other glaucoma medications and used timolol maleate 0.5{\%} twice daily. Primary efficacy variables were IOP and POBF. Results: There was no difference in baseline IOP and POBF parameters between the two study arms. Both D/T and latanoprost statistically significantly reduced IOP by 4.6 mmHg (p<0.0001) and 3.75 mmHg (p< 0.0001) and increased POBF by 2.048 μl/second (p = 0.0030) and 2.147μl/second (p = 0.0009), respectively. Repeated measures ANOVA detected significant changes in POBF with treatment (p = 0.0361). Dorzolamide/timolol fixed combination statistically significantly increased pulse volume by 0.767μl (p = 0.0087), while latanoprost therapy had no significant effect (p = 0.2407). Conclusions: Both drugs had similar effects in terms of IOP reduction. Dorzolamide/timolol significantly increased pulse volume while latanoprost had no effect. Further studies are necessary to establish whether the enhancement of choroidal blood flow can prevent glaucoma progression.",
keywords = "Glaucoma, Intraocular pressure, Pulsatile ocular blood flow",
author = "Ingrida Janulevicien{\"e} and Alon Harris and L. Kagemann and Brent Siesky and L. McCranor",
year = "2004",
month = "12",
doi = "10.1111/j.1600-0420.2004.00358.x",
language = "English",
volume = "82",
pages = "730--737",
journal = "Acta Ophthalmologica",
issn = "1755-375X",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients

AU - Janulevicienë, Ingrida

AU - Harris, Alon

AU - Kagemann, L.

AU - Siesky, Brent

AU - McCranor, L.

PY - 2004/12

Y1 - 2004/12

N2 - Purpose: To evaluate the effects of dorzolamide/timolol fixed combination (D/T) compared to latanoprost on intraocular pressure (IOP) and pulsatile ocular blood flow (POBF) in primary open-angle glaucoma (POAG) patients. Methods: Thirty patients with POAG were randomized in an open-label, cross-over study. Intraocular pressure reduction was achieved by 4 weeks medical therapy with D/T twice daily or latanoprost 0.005% dosed once in the evening. During a 4-week run-in and a 4-week wash-out period between study arms, patients ceased use of all other glaucoma medications and used timolol maleate 0.5% twice daily. Primary efficacy variables were IOP and POBF. Results: There was no difference in baseline IOP and POBF parameters between the two study arms. Both D/T and latanoprost statistically significantly reduced IOP by 4.6 mmHg (p<0.0001) and 3.75 mmHg (p< 0.0001) and increased POBF by 2.048 μl/second (p = 0.0030) and 2.147μl/second (p = 0.0009), respectively. Repeated measures ANOVA detected significant changes in POBF with treatment (p = 0.0361). Dorzolamide/timolol fixed combination statistically significantly increased pulse volume by 0.767μl (p = 0.0087), while latanoprost therapy had no significant effect (p = 0.2407). Conclusions: Both drugs had similar effects in terms of IOP reduction. Dorzolamide/timolol significantly increased pulse volume while latanoprost had no effect. Further studies are necessary to establish whether the enhancement of choroidal blood flow can prevent glaucoma progression.

AB - Purpose: To evaluate the effects of dorzolamide/timolol fixed combination (D/T) compared to latanoprost on intraocular pressure (IOP) and pulsatile ocular blood flow (POBF) in primary open-angle glaucoma (POAG) patients. Methods: Thirty patients with POAG were randomized in an open-label, cross-over study. Intraocular pressure reduction was achieved by 4 weeks medical therapy with D/T twice daily or latanoprost 0.005% dosed once in the evening. During a 4-week run-in and a 4-week wash-out period between study arms, patients ceased use of all other glaucoma medications and used timolol maleate 0.5% twice daily. Primary efficacy variables were IOP and POBF. Results: There was no difference in baseline IOP and POBF parameters between the two study arms. Both D/T and latanoprost statistically significantly reduced IOP by 4.6 mmHg (p<0.0001) and 3.75 mmHg (p< 0.0001) and increased POBF by 2.048 μl/second (p = 0.0030) and 2.147μl/second (p = 0.0009), respectively. Repeated measures ANOVA detected significant changes in POBF with treatment (p = 0.0361). Dorzolamide/timolol fixed combination statistically significantly increased pulse volume by 0.767μl (p = 0.0087), while latanoprost therapy had no significant effect (p = 0.2407). Conclusions: Both drugs had similar effects in terms of IOP reduction. Dorzolamide/timolol significantly increased pulse volume while latanoprost had no effect. Further studies are necessary to establish whether the enhancement of choroidal blood flow can prevent glaucoma progression.

KW - Glaucoma

KW - Intraocular pressure

KW - Pulsatile ocular blood flow

UR - http://www.scopus.com/inward/record.url?scp=11244321804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244321804&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0420.2004.00358.x

DO - 10.1111/j.1600-0420.2004.00358.x

M3 - Article

VL - 82

SP - 730

EP - 737

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 1755-375X

IS - 6

ER -